Targeting cancer with small molecule kinase inhibitors

@article{Zhang2009TargetingCW,
  title={Targeting cancer with small molecule kinase inhibitors},
  author={Jianmin Zhang and Priscilla L Yang and N. Gray},
  journal={Nature Reviews Cancer},
  year={2009},
  volume={9},
  pages={28-39}
}
Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective… Expand
Targeting cancer with kinase inhibitors.
TLDR
There are numerous prospects for the discovery of novel kinase targets, and cancer immunotherapy is explored as a new and promising research area for studying kinase biology. Expand
Covalent Kinase Inhibitors for Cancer
The fundamental signaling role of kinases in cell function and survival has long been recognized as a potentially critical point for pharmacological intervention. Designing covalent inhibitors ofExpand
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
TLDR
Additional factors, including pharmacogenomics, the tumour microenvironment and rapidly acquired drug resistance, also contribute to the clinical sensitivity of various cancers, and should be considered and applied in the development and use of new kinase inhibitors. Expand
Small molecule kinase inhibitors as anti-cancer therapeutics.
TLDR
A broad overview of the relation between mechanism of action and the issues of target selectivity and resistance is provided and special attention was given to the kinase inhibitors currently in clinical trials. Expand
Type II kinase inhibitors: an opportunity in cancer for rational design.
TLDR
This work highlights the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of molecules and presents the strategies for designing druggable molecules that either selectively inhibit target kinases or overcome drug resistance. Expand
Reviewmechanisms of acquired resistance to tyrosine kinase targeted therapy
TLDR
The most recently identified molecular mechanisms that mediate acquired resistance to tyrosine kinase inhibitors are presented through the use of in vitro models or the analysis of patient samples to design better therapies that prevent and overcome resistance to treatment in cancer patients. Expand
Kinase inhibitors: the road ahead
TLDR
An overview of the novel targets, biological processes and disease areas that kinase-targeting small molecules are being developed against, highlight the associated challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors are provided. Expand
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
TLDR
The most recently identified molecular mechanisms that mediate acquired resistance to tyrosine kinase inhibitors are presented through the use of in vitro models or the analysis of patient samples to help design better therapies that prevent and overcome resistance to treatment in cancer patients. Expand
Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
TLDR
It is illustrated that although certain kinase targets may be pharmacologically easily tractable, a better understanding of the regulation and biology of the targets is required to generate drugs that are efficacious in cancer patients. Expand
Carbazole derivatives as kinase-targeting inhibitors for cancer treatment.
Protein Kinases (PKs) are a heterogeneous family of enzymes that modulate several biological pathways, including cell division, cytoskeletal rearrangement, differentiation and apoptosis. InExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 117 REFERENCES
Current development of mTOR inhibitors as anticancer agents
TLDR
The clinical development of this drug class is reviewed and future prospects for incorporating these agents into multitarget or multimodality strategies against cancer are looked at. Expand
Ba/F3 cells and their use in kinase drug discovery
TLDR
Ba/F3 cells are an increasingly popular tool in kinase drug discovery and the ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compound libraries in high-throughput fashion, combined with the use of Ba/F2 cells to predict clinical resistance will greatly facilitate developments in this field. Expand
A small molecule–kinase interaction map for clinical kinase inhibitors
TLDR
An efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases is described, which represents a systematic small molecule-protein interaction map for clinical compounds across a large number of related proteins. Expand
Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.
TLDR
Successful application of a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range. Expand
Recent advances of MEK inhibitors and their clinical progress.
TLDR
The authors summarize the current understanding of science and therapeutic use of the MEK inhibitors targeting the RAS/RAF/ MEK/ERK pathway and recently disclosed MEK inhibitor in two sub-divided classes, ATP noncompetitive and ATP competitive inhibitors are discussed. Expand
Creating chemical diversity to target protein kinases.
TLDR
This review focuses on how selective protein kinase inhibitors that target the ATP and allosteric binding sites are currently being identified and optimized. Expand
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
TLDR
A highly potent and selective small-molecule inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses. Expand
Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors.
TLDR
A recent report describes a chemical proteomics methodology that enables the simultaneous in vivo quantification of the on- and off-binding targets of kinase inhibitors across hundreds of nucleotide-dependent enzymes. Expand
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
TLDR
ON01910, a small molecule inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis, showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors. Expand
New lead generation strategies for protein kinase inhibitors - fragment based screening approaches.
  • A. Gill
  • Medicine, Biology
  • Mini reviews in medicinal chemistry
  • 2004
TLDR
This review discusses how fragment based screening strategies, such as virtual screening, NMR and high-throughput X-ray crystallography are being employed to identify new chemo-types to produce the next generation of protein kinase inhibitors. Expand
...
1
2
3
4
5
...